To further confirm whether JNK and p38 activation contributed to vitamin K2-triggered apoptosis in human bladder cancer cells, SP600125 (a pharmacological inhibitor of JNK) and SB203580 (a pharmacological inhibitor of p38) were used. This evidence concerns the gene MAPK8 and urinary bladder cancer.